Diabetic Neuropathy News and Research

RSS
Diabetic neuropathy is a peripheral nerve disorder caused by diabetes or poor blood sugar control. The most common types of diabetic neuropathy result in problems with sensation in the feet. It can develop slowly after many years of diabetes or may occur early in the disease. The symptoms are numbness, pain, or tingling in the feet or lower legs. The pain can be intense and require treatment to relieve the discomfort. The loss of sensation in the feet may also increase the possibility that foot injuries will go unnoticed and develop into ulcers or lesions that become infected. In some cases, diabetic neuropathy can be associated with difficulty walking and some weakness in the foot muscles. There are other types of diabetic-related neuropathies that affect specific parts of the body. For example, diabetic amyotrophy causes pain, weakness and wasting of the thigh muscles, or cranial nerve infarcts that may result in double vision, a drooping eyelid, or dizziness. Diabetes can also affect the autonomic nerves that control blood pressure, the digestive tract, bladder function, and sexual organs. Problems with the autonomic nerves may cause lightheadedness, indigestion, diarrhea or constipation, difficulty with bladder control, and impotence.
Sangamo's SB-509 fails to meet key endpoints in Phase 2b study for diabetic neuropathy

Sangamo's SB-509 fails to meet key endpoints in Phase 2b study for diabetic neuropathy

Spinifex announces new data from EMA401 pre-clinical study on diabetic neuropathy

Spinifex announces new data from EMA401 pre-clinical study on diabetic neuropathy

NeuroMetrix second quarter total revenues decrease to $2.6 million

NeuroMetrix second quarter total revenues decrease to $2.6 million

Advancements in use of zinc finger nucleases to produce genetically modified pigs

Advancements in use of zinc finger nucleases to produce genetically modified pigs

STSI receives NIH grant to conduct heart-based research

STSI receives NIH grant to conduct heart-based research

Diabetic neuropathy patients with wounds must protect themselves from pets

Diabetic neuropathy patients with wounds must protect themselves from pets

New strategy to prevent amputations

New strategy to prevent amputations

Hopkins research suggests that blood vessels and support cells may be real targets of treatment for diabetic nerve damage

Hopkins research suggests that blood vessels and support cells may be real targets of treatment for diabetic nerve damage

Skin cell-derived CGRP-beta may cause chronic pain

Skin cell-derived CGRP-beta may cause chronic pain

Simple eye scan can detect early signs of diabetes-related nerve damage

Simple eye scan can detect early signs of diabetes-related nerve damage

Sangamo announces presentations of ZFP Therapeutics data at ASGCT 2011

Sangamo announces presentations of ZFP Therapeutics data at ASGCT 2011

Investigational Alzheimer's compounds may treat neuropathies

Investigational Alzheimer's compounds may treat neuropathies

Sangamo prices public offering of 6.7M shares of common stock

Sangamo prices public offering of 6.7M shares of common stock

Diabetes management accepted for coverage by Chemical Abstracts

Diabetes management accepted for coverage by Chemical Abstracts

Sangamo's preclinical ZFN-gene modification studies for HIV/AIDS treatment presented at CROI

Sangamo's preclinical ZFN-gene modification studies for HIV/AIDS treatment presented at CROI

Positive preliminary data from SB-728-902 Phase 1 trial against HIV/AIDS presented at 18th CROI

Positive preliminary data from SB-728-902 Phase 1 trial against HIV/AIDS presented at 18th CROI

Sanofi-aventis, Sunnybrook enter agreement to develop and commercialize vasculotide

Sanofi-aventis, Sunnybrook enter agreement to develop and commercialize vasculotide

Diabetes Management – a new journal addressing the management issues of a complex disease

Diabetes Management – a new journal addressing the management issues of a complex disease

NeuroMetrix fourth quarter total revenues decrease to $3.1 million

NeuroMetrix fourth quarter total revenues decrease to $3.1 million

Discovery of aldose reductase enzyme can result in new therapies for asthma and COPD

Discovery of aldose reductase enzyme can result in new therapies for asthma and COPD